Abstract:
The entry of HIV into target cells is a multistep process involving viral attachment, coreceptor binding, and fusion. Although various inhibitors targeting HIV-1 entry steps have been developed, only maraviroc, a CCR5 antagonist, and enfuvirtide, a fusion inhibitor, are approved for clinical use.1 Attachment inhibitors prevent the initial interaction between virus and host cells by binding to the viral envelope protein gp120 and blocking attachment of the virus to the CD4 receptor. Attempts to bring attachment inhibitors to the clinic did not progress.
Autors: Ballana E, Esté JA.
